GSK (GSK) subsidiary Tesaro has signed an exclusive license agreement with Alteogen, Alteogen said Tuesday.
Under the deal, the company said Tesaro acquired worldwide rights to use its ALT-B4 technology to develop and commercialize a subcutaneous formulation of dostarlimab, a PD-1 blocking antibody.
Alteogen said it will receive a $20 million upfront payment and could earn up to $265 million in milestone payments tied to development, regulatory, and sales targets, along with royalties on commercial sales.
Alteogen will be responsible for clinical and commercial supply of ALT-B4 to Tesaro, it added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.